Tag: geographic atrophy market forecast

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Geographic Atrophy Market Forecast: What Market Value Is Expected By 2030?

The market for geographic atrophy has experienced substantial expansion. Projections indicate a rise from $2.11 billion in 2025 to $2.4 billion in 2026, reflecting a compound annual growth rate of 13.3%. Factors contributing to this historical growth include an increasing elderly demographic, the widespread occurrence of age-related macular degeneration, enhancements in retinal imaging techniques, progress in ophthalmic drug discovery, and increased financial support for clinical research.

The market for geographic atrophy is poised for substantial expansion over the coming years, projected to reach $3.92 billion by 2030, reflecting a compound annual growth rate of 13.1%. This anticipated surge is propelled by several key factors, including the introduction of innovative treatments, the broadening of detection initiatives, the incorporation of artificial intelligence in diagnostic imaging, heightened patient understanding of the condition, and the overall advancement of specialized eye care services. During this projected period, significant trends are expected to shape the landscape, such as an escalating development of complement inhibitor therapies, a heightened emphasis on the early identification of retinal diseases, increased financial backing for pioneering ophthalmic medications, advancements in imaging techniques for disease progression oversight, and a greater number of clinical investigations into AMD treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21984&type=smp

Geographic Atrophy Market Growth Drivers: What Factors Are Accelerating Expansion?

The expanding incidence of macular degeneration linked to aging is anticipated to stimulate the expansion of the geographic atrophy market in the future. This vision impairment, known as age-related macular degeneration (AMD), affects the central retinal area in older individuals, hindering their ability to discern fine details. A primary driver for the heightened occurrence of AMD is the growing elderly demographic; as lifespans increase, the natural aging process gradually compromises eye health, amplifying susceptibility to the condition. Interventions for geographic atrophy aid those with AMD by mitigating the advancement of retinal deterioration and safeguarding remaining sight. For illustration, a report from Medical News Today, a US-based digital media entity, indicated in January 2024 that worldwide AMD diagnoses are projected to climb from 196 million to 288 million by the year 2040. Consequently, the escalating prevalence of age-related macular degeneration is a key factor fueling the geographic atrophy market’s growth.

Geographic Atrophy Market Segmentation: How Is The Market Structured Across Key Categories?

The geographic atrophy market covered in this report is segmented –

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drug Types

2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan, Lfg316

3) By Neuroprotective Agents: Latanoprost, Brimonidine

4) By Other Drug Types: Steroids, Retinoids, Combination Therapy

Geographic Atrophy Market Trends: What Is Shaping Future Industry Growth?

Leading entities within the geographic atrophy sector are concentrating their efforts on pioneering treatments, notably complement inhibitor therapy, to advance therapeutic options for this condition. Complement inhibitor therapy functions by moderating an excessively active immune system associated with particular ailments, thereby safeguarding healthy cells from harm and mitigating disease advancement. Illustratively, in February of 2025, Astellas Pharma Inc., a pharmaceutical firm headquartered in Japan, revealed the Food and Drug Administration’s endorsement of IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy; this regulatory agency is based in the United States. This clearance permits IZERVAY to be administered without any temporal restrictions on dosage frequency for the treatment of geographic atrophy (GA) that is a consequence of age-related macular degeneration (AMD), thereby furnishing enhanced adaptability in GA management and presenting extended treatment possibilities for individuals receiving care and the medical professionals overseeing it.

Geographic Atrophy Market Competitive Landscape And Leading Companies

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics

Access The Complete Geographic Atrophy Market Report:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Geographic Atrophy Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the geographic atrophy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Geographic Atrophy Market Forecast: What Market Value Is Expected By 2030?

The market for geographic atrophy has experienced substantial expansion. Projections indicate a rise from $2.11 billion in 2025 to $2.4 billion in 2026, reflecting a compound annual growth rate of 13.3%. Factors contributing to this historical growth include an increasing elderly demographic, the widespread occurrence of age-related macular degeneration, enhancements in retinal imaging techniques, progress in ophthalmic drug discovery, and increased financial support for clinical research.

The market for geographic atrophy is poised for substantial expansion over the coming years, projected to reach $3.92 billion by 2030, reflecting a compound annual growth rate of 13.1%. This anticipated surge is propelled by several key factors, including the introduction of innovative treatments, the broadening of detection initiatives, the incorporation of artificial intelligence in diagnostic imaging, heightened patient understanding of the condition, and the overall advancement of specialized eye care services. During this projected period, significant trends are expected to shape the landscape, such as an escalating development of complement inhibitor therapies, a heightened emphasis on the early identification of retinal diseases, increased financial backing for pioneering ophthalmic medications, advancements in imaging techniques for disease progression oversight, and a greater number of clinical investigations into AMD treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21984&type=smp

Geographic Atrophy Market Growth Drivers: What Factors Are Accelerating Expansion?

The expanding incidence of macular degeneration linked to aging is anticipated to stimulate the expansion of the geographic atrophy market in the future. This vision impairment, known as age-related macular degeneration (AMD), affects the central retinal area in older individuals, hindering their ability to discern fine details. A primary driver for the heightened occurrence of AMD is the growing elderly demographic; as lifespans increase, the natural aging process gradually compromises eye health, amplifying susceptibility to the condition. Interventions for geographic atrophy aid those with AMD by mitigating the advancement of retinal deterioration and safeguarding remaining sight. For illustration, a report from Medical News Today, a US-based digital media entity, indicated in January 2024 that worldwide AMD diagnoses are projected to climb from 196 million to 288 million by the year 2040. Consequently, the escalating prevalence of age-related macular degeneration is a key factor fueling the geographic atrophy market’s growth.

Geographic Atrophy Market Segmentation: How Is The Market Structured Across Key Categories?

The geographic atrophy market covered in this report is segmented –

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drug Types

2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan, Lfg316

3) By Neuroprotective Agents: Latanoprost, Brimonidine

4) By Other Drug Types: Steroids, Retinoids, Combination Therapy

Geographic Atrophy Market Trends: What Is Shaping Future Industry Growth?

Leading entities within the geographic atrophy sector are concentrating their efforts on pioneering treatments, notably complement inhibitor therapy, to advance therapeutic options for this condition. Complement inhibitor therapy functions by moderating an excessively active immune system associated with particular ailments, thereby safeguarding healthy cells from harm and mitigating disease advancement. Illustratively, in February of 2025, Astellas Pharma Inc., a pharmaceutical firm headquartered in Japan, revealed the Food and Drug Administration’s endorsement of IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy; this regulatory agency is based in the United States. This clearance permits IZERVAY to be administered without any temporal restrictions on dosage frequency for the treatment of geographic atrophy (GA) that is a consequence of age-related macular degeneration (AMD), thereby furnishing enhanced adaptability in GA management and presenting extended treatment possibilities for individuals receiving care and the medical professionals overseeing it.

Geographic Atrophy Market Competitive Landscape And Leading Companies

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics

Access The Complete Geographic Atrophy Market Report:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Geographic Atrophy Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the geographic atrophy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Geographic Atrophy Market Forecast: What Market Value Is Expected By 2030?

The market for geographic atrophy has experienced substantial expansion. Projections indicate a rise from $2.11 billion in 2025 to $2.4 billion in 2026, reflecting a compound annual growth rate of 13.3%. Factors contributing to this historical growth include an increasing elderly demographic, the widespread occurrence of age-related macular degeneration, enhancements in retinal imaging techniques, progress in ophthalmic drug discovery, and increased financial support for clinical research.

The market for geographic atrophy is poised for substantial expansion over the coming years, projected to reach $3.92 billion by 2030, reflecting a compound annual growth rate of 13.1%. This anticipated surge is propelled by several key factors, including the introduction of innovative treatments, the broadening of detection initiatives, the incorporation of artificial intelligence in diagnostic imaging, heightened patient understanding of the condition, and the overall advancement of specialized eye care services. During this projected period, significant trends are expected to shape the landscape, such as an escalating development of complement inhibitor therapies, a heightened emphasis on the early identification of retinal diseases, increased financial backing for pioneering ophthalmic medications, advancements in imaging techniques for disease progression oversight, and a greater number of clinical investigations into AMD treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21984&type=smp

Geographic Atrophy Market Growth Drivers: What Factors Are Accelerating Expansion?

The expanding incidence of macular degeneration linked to aging is anticipated to stimulate the expansion of the geographic atrophy market in the future. This vision impairment, known as age-related macular degeneration (AMD), affects the central retinal area in older individuals, hindering their ability to discern fine details. A primary driver for the heightened occurrence of AMD is the growing elderly demographic; as lifespans increase, the natural aging process gradually compromises eye health, amplifying susceptibility to the condition. Interventions for geographic atrophy aid those with AMD by mitigating the advancement of retinal deterioration and safeguarding remaining sight. For illustration, a report from Medical News Today, a US-based digital media entity, indicated in January 2024 that worldwide AMD diagnoses are projected to climb from 196 million to 288 million by the year 2040. Consequently, the escalating prevalence of age-related macular degeneration is a key factor fueling the geographic atrophy market’s growth.

Geographic Atrophy Market Segmentation: How Is The Market Structured Across Key Categories?

The geographic atrophy market covered in this report is segmented –

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drug Types

2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan, Lfg316

3) By Neuroprotective Agents: Latanoprost, Brimonidine

4) By Other Drug Types: Steroids, Retinoids, Combination Therapy

Geographic Atrophy Market Trends: What Is Shaping Future Industry Growth?

Leading entities within the geographic atrophy sector are concentrating their efforts on pioneering treatments, notably complement inhibitor therapy, to advance therapeutic options for this condition. Complement inhibitor therapy functions by moderating an excessively active immune system associated with particular ailments, thereby safeguarding healthy cells from harm and mitigating disease advancement. Illustratively, in February of 2025, Astellas Pharma Inc., a pharmaceutical firm headquartered in Japan, revealed the Food and Drug Administration’s endorsement of IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy; this regulatory agency is based in the United States. This clearance permits IZERVAY to be administered without any temporal restrictions on dosage frequency for the treatment of geographic atrophy (GA) that is a consequence of age-related macular degeneration (AMD), thereby furnishing enhanced adaptability in GA management and presenting extended treatment possibilities for individuals receiving care and the medical professionals overseeing it.

Geographic Atrophy Market Competitive Landscape And Leading Companies

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics

Access The Complete Geographic Atrophy Market Report:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Geographic Atrophy Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the geographic atrophy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Geographic Atrophy Market Between 2026 And 2030?

The geographic atrophy market size has experienced rapid growth in recent years. It is projected to expand from $2.11 billion in 2025 to $2.4 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.3%. This historic growth can be attributed to factors such as the increase in the aging population, the prevalence of age-related macular degeneration, advancements in retinal imaging, early ophthalmic drug development efforts, and clinical research funding.

The geographic atrophy market size is anticipated to undergo swift expansion in the upcoming years. It is forecast to achieve a value of $3.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. The growth anticipated during this forecast period can be ascribed to several factors, including the approval of innovative therapies, the broadening of screening programs, the incorporation of AI-based imaging solutions, heightened patient awareness, and the advancement of specialty eye care. Significant trends expected in the forecast period involve the increasing development of complement inhibitor treatments, a concentrated effort on the early diagnosis of retinal disorders, augmented investment in new ophthalmic drugs, the wider adoption of imaging technologies for tracking disease progression, and a rise in clinical trials for AMD treatments.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

What Factors Are Contributing To The Growth Of The Geographic Atrophy Market?

The rising prevalence of age-related macular degeneration is anticipated to drive the expansion of the geographic atrophy market in the coming period. Age-related macular degeneration (AMD) is an ocular condition that harms the central part of the retina in older individuals, making it challenging to see intricate details. The aging demographic serves as a primary driver for the widespread occurrence of age-related macular degeneration, given that increased longevity and the natural aging process progressively damage the eyes, rendering them more susceptible to the disease over time. Treatments for geographic atrophy assist age-related macular degeneration (AMD) patients by decelerating the progression of retinal damage and safeguarding their existing vision. For instance, in January 2024, a report published by Medical News Today, a US-based digital media company, forecast that global cases of age-related macular degeneration are expected to increase from 196 million to 288 million by 2040. Consequently, the escalating prevalence of age-related macular degeneration is fueling the growth of the geographic atrophy market.

How Is The Geographic Atrophy Market Broken Down By Segment Categories?

The geographic atrophy market covered in this report is segmented –

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drug Types

2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan, Lfg316

3) By Neuroprotective Agents: Latanoprost, Brimonidine

4) By Other Drug Types: Steroids, Retinoids, Combination Therapy

What Trends Are Shaping The Future Of The Geographic Atrophy Market?

Major companies operating in the geographic atrophy market are concentrating on innovative therapies like complement inhibitor therapy to develop advanced treatments for geographic atrophy. Complement inhibitor therapy is a treatment designed to slow an overactive immune response linked to certain diseases, helping to protect healthy cells from damage and reduce disease progression. For instance, in February 2025, Astellas Pharma Inc., a Japan-based pharmaceutical company, announced that IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy received approval from the Food and Drug Administration, a US-based government agency. This approval permits IZERVAY to be utilized without a limitation on the duration of dosing for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This decision offers enhanced flexibility for managing GA, providing longer-term treatment options for both patients and healthcare providers.

Which Players Are Present In The Geographic Atrophy Market Space?

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics

Get The Full Geographic Atrophy Market Report:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Which Region Leads The Geographic Atrophy Market In Terms Of Market Share?

North America was the largest region in the geographic atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Geographic Atrophy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Browse Through More Reports Similar to the Global Geographic Atrophy Market 2026, By The Business Research Company

Athleisure Market Report 2026

https://www.thebusinessresearchcompany.com/report/athleisure-global-market-report

Geographic Information System Market Report 2026

https://www.thebusinessresearchcompany.com/report/geographic-information-system-global-market-report

Geotourism Market Report 2026

https://www.thebusinessresearchcompany.com/report/geotourism-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Geographic Atrophy Market Between 2026 And 2030?

The geographic atrophy market size has experienced rapid expansion in recent years. It is projected to increase from $2.11 billion in 2025 to $2.4 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.3%. This growth during the historic period can be linked to factors such as aging population growth, the prevalence of age-related macular degeneration, advances in retinal imaging, early ophthalmic drug development, and clinical research funding.

The geographic atrophy market size is projected to experience substantial growth in the upcoming years. It is predicted to reach $3.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This expansion during the forecast period is primarily driven by the approval of novel therapies, the broadening of screening programs, the integration of AI-based imaging, heightened patient awareness, and the growth of specialty eye care services. Significant trends identified for this period include the rising development of complement inhibitor therapies, an increasing focus on the early diagnosis of retinal disorders, greater investment in novel ophthalmic drugs, the expansion of imaging technologies for disease monitoring, and an increase in clinical trials for AMD treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21984&type=smp

What Key Drivers Are Influencing The Growth Of The Geographic Atrophy Market?

The geographic atrophy market is anticipated to expand due to the rising occurrence of age-related macular degeneration. Age-related macular degeneration (AMD) refers to an eye ailment that impairs the central retina in older individuals, hindering their ability to discern fine details. The primary factor contributing to the widespread nature of age-related macular degeneration is the aging population, as extended lifespans and the natural process of aging progressively harm the eyes, increasing their susceptibility to the condition over time. Treatments for geographic atrophy assist patients with age-related macular degeneration (AMD) by decelerating the advancement of retinal damage and safeguarding existing vision. Illustratively, a January 2024 report from Medical News Today, a US-based digital media company, projects that global cases of age-related macular degeneration will increase from 196 million to 288 million by 2040. Consequently, the growing prevalence of age-related macular degeneration is fueling the expansion of the geographic atrophy market.

Which Market Segments Are Examined In The Geographic Atrophy Market Study?

The geographic atrophy market covered in this report is segmented –

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drug Types

2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan, Lfg316

3) By Neuroprotective Agents: Latanoprost, Brimonidine

4) By Other Drug Types: Steroids, Retinoids, Combination Therapy

What Key Trends Are Influencing The Development Of The Geographic Atrophy Market?

Leading companies in the geographic atrophy market are dedicating efforts to pioneering therapies, such as complement inhibitor therapy, to create more advanced treatments for geographic atrophy. Complement inhibitor therapy functions by mitigating an overactive immune response linked to certain diseases, helping to protect healthy cells from damage and slow down disease progression. For instance, in February 2025, Astellas Pharma Inc., a Japan-based pharmaceutical company, announced the Food and Drug Administration, a US-based government agency, had approved IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy. This approval allows IZERVAY to be administered without limits on the duration of dosing for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This decision offers increased adaptability for managing GA, providing patients and healthcare providers with longer-term treatment options.

Who Are The Primary Competitors In The Geographic Atrophy Market?

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics

Read the full geographic atrophy market report here:

https://www.thebusinessresearchcompany.com/report/geographic-atrophy-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Geographic Atrophy Market?

North America was the largest region in the geographic atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Geographic Atrophy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21984&type=smp

Browse Through More Reports Similar to the Global Geographic Atrophy Market 2026, By The Business Research Company

Excavator Global Market Report

https://www.thebusinessresearchcompany.com/report/excavator-global-market-report

Vanadium Global Market Report

https://www.thebusinessresearchcompany.com/report/vanadium-global-market-report

Genotyping Global Market Report

https://www.thebusinessresearchcompany.com/report/genotyping-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model